Damara Ortiz

494 total citations
14 papers, 127 citations indexed

About

Damara Ortiz is a scholar working on Physiology, Organic Chemistry and Rheumatology. According to data from OpenAlex, Damara Ortiz has authored 14 papers receiving a total of 127 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Physiology, 4 papers in Organic Chemistry and 4 papers in Rheumatology. Recurrent topics in Damara Ortiz's work include Lysosomal Storage Disorders Research (6 papers), Glycogen Storage Diseases and Myoclonus (4 papers) and Carbohydrate Chemistry and Synthesis (3 papers). Damara Ortiz is often cited by papers focused on Lysosomal Storage Disorders Research (6 papers), Glycogen Storage Diseases and Myoclonus (4 papers) and Carbohydrate Chemistry and Synthesis (3 papers). Damara Ortiz collaborates with scholars based in United States, Austria and Denmark. Damara Ortiz's co-authors include Julie Yu, Iacopo Olivotto, Ulla Feldt‐Rasmussen, Khan Nedd, Gere Sunder‐Plassmann, Takashi Hamazaki, Nina Skuban, Kathy Nicholls, Toya Ohashi and Jay Barth and has published in prestigious journals such as Human Genetics, Molecular Genetics and Metabolism and Cytogenetic and Genome Research.

In The Last Decade

Damara Ortiz

12 papers receiving 123 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Damara Ortiz United States	6	85	40	40	34	28	14	127
Simone Scalia Italy	7	162 1.9×	60 1.5×	56 1.4×	52 1.5×	46 1.6×	13	206
Khan Nedd United States	5	138 1.6×	35 0.9×	43 1.1×	69 2.0×	50 1.8×	6	150
Andressa Federhen Brazil	5	115 1.4×	21 0.5×	34 0.8×	59 1.7×	23 0.8×	12	136
María José Coll Spain	3	114 1.3×	37 0.9×	16 0.4×	37 1.1×	18 0.6×	4	133
Gustavo Charria-Ortiz United States	3	154 1.8×	23 0.6×	64 1.6×	48 1.4×	38 1.4×	4	187
María Verónica Muñoz Rojas Brazil	5	145 1.7×	17 0.4×	69 1.7×	54 1.6×	37 1.3×	7	161
Aurelio Hernández‐Laín Spain	6	30 0.4×	48 1.2×	73 1.8×	13 0.4×	15 0.5×	22	130
Sonia Segovia Spain	7	77 0.9×	42 1.1×	58 1.4×	25 0.7×	14 0.5×	15	174
M. Sellos-Moura United States	5	56 0.7×	56 1.4×	12 0.3×	20 0.6×	11 0.4×	6	109
Mehul Mistri India	10	193 2.3×	78 1.9×	14 0.3×	68 2.0×	49 1.8×	30	253

Countries citing papers authored by Damara Ortiz

Since Specialization

Citations

This map shows the geographic impact of Damara Ortiz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Damara Ortiz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Damara Ortiz more than expected).

Fields of papers citing papers by Damara Ortiz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Damara Ortiz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Damara Ortiz. The network helps show where Damara Ortiz may publish in the future.

Co-authorship network of co-authors of Damara Ortiz

This figure shows the co-authorship network connecting the top 25 collaborators of Damara Ortiz. A scholar is included among the top collaborators of Damara Ortiz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Damara Ortiz. Damara Ortiz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Ramaswami, Uma, Esperanza Font–Montgomery, Özlem Göker-Alpan, et al.. (2025). Safety and efficacy of migalastat in adolescent patients with Fabry disease: Results from ASPIRE, a phase 3b, open-label, single-arm, 12-month clinical trial, and its open-label extension. Molecular Genetics and Metabolism. 145(1). 109102–109102. 3 indexed citations

Thomas, Mark, Jerry Vockley, Damara Ortiz, et al.. (2025). Phase 1/2 clinical trial evaluating 4D-310 in adults with Fabry disease cardiomyopathy: Interim analysis of cardiac and safety outcomes in patients with 21–42 months of follow up. Molecular Genetics and Metabolism. 144(2). 108965–108965. 1 indexed citations

Ortiz, Damara, et al.. (2024). Genetic counselors' awareness and attitudes regarding gene therapies. Journal of Genetic Counseling. 34(2). e1953–e1953.

Williams, Lee, et al.. (2023). Overview of Newborn Screening of Lysosomal Storage Diseases for Pediatric Care Providers. 7(3). 1–12. 1 indexed citations

Schiffmann, Raphael, Özlem Göker-Alpan, Jerry Vockley, et al.. (2023). Cardiac effects of 4D-310 in adults with Fabry disease in a phase 1/2 clinical trial: Functional, quality of life, and imaging endpoints in patients with 12 months of follow up. Molecular Genetics and Metabolism. 138(2). 107306–107306. 6 indexed citations

Yatsenko, Svetlana A., Mahmoud Aarabi, Jie Hu, et al.. (2020). Copy number alterations involving 59 ACMG ‐recommended secondary findings genes. Clinical Genetics. 98(6). 577–588. 3 indexed citations

Fıçıcıoğlu, Can, Rebecca C. Ahrens‐Nicklas, James C. DiPerna, et al.. (2020). Newborn Screening for Pompe Disease: Pennsylvania Experience. International Journal of Neonatal Screening. 6(4). 89–89. 29 indexed citations

Feldt‐Rasmussen, Ulla, Derralynn Hughes, Gere Sunder‐Plassmann, et al.. (2020). Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study. Molecular Genetics and Metabolism. 131(1-2). 219–228. 53 indexed citations

Burk, Caitlin M., Emily M. Mace, Bret L. Bostwick, et al.. (2019). Immunodeficiency, centromeric instability, and facial anomalies (ICF) syndrome with NK dysfunction and EBV-driven malignancy treated with stem cell transplantation. The Journal of Allergy and Clinical Immunology In Practice. 8(3). 1103–1106.e3. 6 indexed citations

10.

Feldt‐Rasmussen, Ulla, Derralynn Hughes, Gere Sunder‐Plassmann, et al.. (2019). Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 30-month results from the randomized phase 3 ATTRACT study. Molecular Genetics and Metabolism. 126(2). S53–S53.

11.

Ortiz, Damara, et al.. (2019). Increased frequency of enzyme replacement therapy in a Fabry disease cohort. Molecular Genetics and Metabolism. 126(2). S70–S70. 1 indexed citations

12.

Ou, Zhishuo, et al.. (2018). Partial 5p Deletion and Partial 5q Duplication in a Patient with Multiple Congenital Anomalies: A Two-Step Mechanism in Chromosomal Rearrangement Mediated by Non-Allelic Homologous Recombination. Cytogenetic and Genome Research. 156(2). 65–70. 1 indexed citations

13.

Sogawa, Yoshimi, et al.. (2018). A case of de novo NAA10 mutation presenting with eyelid myoclonias (AKA Jeavons syndrome). Seizure. 60. 120–122. 13 indexed citations

14.

Leduc, Magalie S., Marianne McGuire, Suneeta Madan‐Khetarpal, et al.. (2018). De novo apparent loss-of-function mutations in PRR12 in three patients with intellectual disability and iris abnormalities. Human Genetics. 137(3). 257–264. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact